67Cu-SARTATE not checked

Clarity Pharmaceuticals Ltd · Cu-67 SARTATE · copper 67 SARTATE

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
Main trialPhase 1/2
“The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.”In the company’s words, NCT04023331 on ClinicalTrials.gov
Other names
Cu-67 SARTATE · copper 67 SARTATE

Other drugs for Neuroblastoma

All 12 drugs for Neuroblastoma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Terminated 24 Jan 2025 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow 67Cu-SARTATE

Following is part of Solo: you see every change to 67Cu-SARTATE the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in